TheraRadar
Clinical-Stage Companies / Lepu Biopharma

Lepu Biopharma

Pre-Approval PRO BETA
16
Total Trials
3
Phase 3
12
Phase 2
8
Recruiting
184
Score

Pipeline by Phase

Phase 3
3
Phase 2
12
Phase 1
6

Therapeutic Focus

Advanced Solid Tumors Recurrent or Metastatic Nasopharyngeal Carcinoma Advanced or Metastatic Solid Tumors Non Muscle Invasive Bladder Cancer High-grade Ta/ T1 Papillary Disease Bladder Cancer

Clinical Trials (16)

NCT06976190 Phase 3 RECRUITING

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Started: 5/6/2025

NCT05751512 Phase 3 RECRUITING

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Started: 4/4/2023

NCT07138846 Phase 3 NOT YET RECRUITING

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Started: 1/1/2027

NCT07283835 Phase 2 RECRUITING

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Started: 12/4/2025

NCT07586124 Phase 2 RECRUITING

Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

Started: 7/6/2026

NCT05126719 Phase 2 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Started: 4/6/2023

NCT04868162 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Started: 4/23/2021

NCT05188209 Phase 2 TERMINATED

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Started: 12/31/2021

NCT04838548 Phase 2 COMPLETED

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Started: 4/16/2021

NCT04838964 Phase 2 COMPLETED

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Started: 5/18/2021

NCT07479485 Phase 1 RECRUITING

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Started: 4/8/2026

NCT07093970 Phase 1 RECRUITING

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

Started: 7/24/2024

NCT05688605 Phase 1 RECRUITING

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Started: 6/30/2022

NCT04843709 Phase 1 COMPLETED

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Started: 7/26/2021

NCT04868344 Phase 1 COMPLETED

A Study of MRG003 in Patients With Advanced Solid Tumors

Started: 5/9/2018

NCT07737600 Phase 1 NOT YET RECRUITING

A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

Started: 8/1/2026

Drug Candidates

MRG004A Cretostimogene Grenadenorepvec MRG006A Pucotenlimab PD1/VEGF antibody TKI MRG003 MRG003 + Pucotenlimab Gemcitabine, Docetaxel, or Capecitabine MRG004A plus best supportive care
Activity Status: Active
Last Trial Started: 1/1/2027
Last Trial Ended: 7/26/2024
Trials (12 months): 5
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.